Newsletter | January 13, 2025

01.13.25 -- It's Partly Personal (Medicine): In 10 Years Outsourcing At $315 Billion

SPONSOR

Nanotechnology To Improve The Performance Of Your Small And Large Molecule Medicines

Christian Jones shares the latest in nanotechnology advancements including recent clinical data, formulation applications, and API optimization to NanoImprove formulations through superior bioavailability, drug loading, route of administration, pill burden, and more.

FEATURED EDITORIAL

It's Partly Personal (Medicine): In 10 Years Outsourcing At $315 Billion

You’ve got to give Towards Healthcare credit. They've the fortitude to publish a 10-year projection of how much development and manufacturing outsourcing will add up to globally. Interestingly, personalized medicine may play an outsized role in that growth. Chief Editor Louis Garguilo takes a deeper dive into the Pharmaceutical CDMO Market Companies, Advantages and Segmental Analysis.

Can Our Current Operational Processes Survive In 2025 And Beyond?

As long as operating procedure improvements are confined to a single function or sub-area, the benefits will be limited to that context. What can we do for true process improvement across our organization?

INDUSTRY INSIGHTS

How To Establish Effective, Scalable Drug Safety Ops Across Vendors

Numerous factors impact a drug safety program, but proper management of three key elements drives success while creating a scalable drug safety model.

Strike The Balance Between Cost-Effective And Risk-Averse Biologic Manufacturing

As drug sponsors continue to navigate increasing global demand for complex biologics, it is vital to assess which outsourcing strategies mitigate risk while maintaining budgets and timelines.

Transitioning From Research To Drug Formulation And Development

The transition from academic research and studies to industry research demands that individuals master additional skills, set different objectives, and define “success” differently.

Reducing ADC Timelines With Integrated Development And Manufacturing

ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.

How To Maximize Cell Line Productivity And Efficiency

Explore some of the key considerations in cell line development, how advances in technology are improving the efficiency and productivity of cell lines, and the future of cell line development.

Process Optimization For mAb Commercial Manufacturing

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

Manufacturing Strategies And Facility Design For Patient-Centric Delivery

De-risk supply chains, accelerate time to market, and reduce costs by selecting an optimal manufacturing strategy and leveraging technologies for efficient and scalable production of proteins.

SPONSOR

2025 BioPlan's 22nd Annual Survey--Biopharmaceutical Manufacturing

For over 20 years, we continue to be the leader in providing the biopharma industry's most comprehensive benchmarking analysis. We invite you to participate in our 22nd Annual Survey in Biopharmaceutical Manufacturing! For all completed, qualified responses, we'll send an Amazon egift card, a copy of the summary results (mid-2025), and our 2025 Top Trends in Biomanufacturing White Paper.

SOLUTIONS

Capacity Update October 2024: Large Molecule Drug Substance

Senior Business Development Director Rose Rhomberg presents an in-depth look at Cytovance’s capabilities and highlights the available capacity designed to accelerate your goals.

Capacity Update October 2024: ADC

This presentation underscores the essential role of comprehensive characterization in ensuring that ADCs not only meet regulatory standards but also achieve therapeutic goals.

Capacity Update October 2024: Large Molecule Drug Substance

Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.

Improving Cell Line Development Efficiency With AbZelect

By streamlining timelines and reducing risks in downstream processes, our solutions enhance efficiency, helping developers navigate the IND pathway and meet milestones with confidence.

OUTSOURCED PHARMA CAPACITY UPDATE

Find Your New CDMO At Outsourced Pharma Capacity Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: